Inovio Pharmaceuticals
158 hedge funds and large institutions have $327M invested in Inovio Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 73 funds opening new positions, 44 increasing their positions, 30 reducing their positions, and 18 closing their positions.
306% more first-time investments, than exits
New positions opened: 73 | Existing positions closed: 18
105% more capital invested
Capital invested by funds: $160M → $327M (+$168M)
62% more call options, than puts
Call options by funds: $36M | Put options by funds: $22.2M
49% more funds holding
Funds holding: 106 → 158 (+52)
47% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 30
1.52% less ownership
Funds ownership: 4.04% → 2.52% (-1.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$8.61M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$6.6M |
| 3 |
BlackRock
New York
|
+$5.1M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.78M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$1.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$19.9M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$15.1M |
| 3 |
NAMA
Nikko Asset Management Americas
New York
|
-$12M |
| 4 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$12M |
| 5 |
Morgan Stanley
New York
|
-$5.97M |
INO Hedge Fund Activity: Q1 2020 in Review
158 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q1 2020, worth a combined $327M — up 105% from $160M a quarter earlier.
Buyers outnumbered sellers: 73 funds opened new INO positions and 18 closed out — a net gain of 55 holders — while 44 added to existing stakes and 30 trimmed.
The largest buyer was Millennium Management, adding an estimated $8.61M. The largest seller was Wasatch Advisors, cutting an estimated $19.9M.
- 158 institutional investors held Inovio Pharmaceuticals (INO) as of Q1 2020, up from 106 in Q4 2019.
- Funds reported $327M of Inovio Pharmaceuticals stock for Q1 2020, up 105% quarter-over-quarter.
- 73 funds opened new Inovio Pharmaceuticals positions in Q1 2020 and 18 closed out, a net change of +55 holders.
- The largest Inovio Pharmaceuticals buyer in Q1 2020 was Millennium Management, an estimated $8.61M added.
- The largest Inovio Pharmaceuticals seller in Q1 2020 was Wasatch Advisors, an estimated $19.9M sold.
Based on aggregated 13F filings for Q1 2020.